Pridopidine hydrochloride is under clinical development by Prilenia Therapeutics Development and currently in Phase III for Huntington Disease. According to GlobalData, Phase III drugs for Huntington Disease does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Pridopidine hydrochloride LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pridopidine hydrochloride overview
Pridopidine hydrochloride (ACR-16, Huntexil, ASP-2314) is under development for the treatment of Huntington disease, amyotrophic lateral sclerosis, neurodegenerative eye disease, Parkinson’s disease, Rett syndrome, fragile X syndrome and Alzheimer's disease. The drug candidate is administered orally in the form of capsule. It acts by targeting dopamine receptor D2 and sigma-1 receptor.
It was also under development for the treatment of motor disorders including schizophrenia and Parkinson’s disease levodopa induced dyskinesia (PD-LID).
Prilenia Therapeutics Development overview
Prilenia Therapeutics Development (Prilenia) is a biotechnology company that develops therapies to treat neurobehavioral disorders and neurodegenerative diseases in adults and children. The company is investigating its lead product candidate Pridopidine, a small molecule drug against Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), and dyskinesia associated with levodopa drug which is used to treat Parkinson’s disease. It is also evaluating its lead product to treat neurodegenerative eye diseases, Parkinson’s disease, Rett syndrome, Fragile X syndrome, and Alzheimer’s disease. Prilenia funding partners include Forbion Capital Partners, Talisman Capital Partners, Morningside Ventures and Sectoral Asset Management. The company has an operational presence in the Netherlands. Prilenia is headquartered in Herzliya, Tel Aviv, Israel.
For a complete picture of Pridopidine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.